Market Place
Sourcing Support
Crescita Reports Q3 2024 Results
06 Nov 2024 //
BUSINESSWIRE
Crescita To Present At Planet MicroCap Showcase: VANCOUVER 2024
12 Sep 2024 //
BUSINESSWIRE
Canadian Healthcare Provider Selects Crescita As Exclusive Manufacturer
19 Jul 2024 //
BUSINESSWIRE
Crescita Adds MicronJetTM600 To Medical Aesthetic Portfolio
17 Jul 2024 //
BUSINESSWIRE
Crescita Completes Acquisition of Strategic Assets of Occy Laboratory
26 Jun 2024 //
BUSINESSWIRE
Crescita to Acquire Strategic Assets of Occy Laboratory
20 Jun 2024 //
BUSINESSWIRE
Crescita Reports First Quarter 2024 Results
08 May 2024 //
BUSINESSWIRE
Crescita Reports Third Quarter 2023 Results
08 Nov 2023 //
BUSINESSWIRE
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
29 Aug 2023 //
BUSINESSWIRE
Crescita Announces the Results of its Annual General and Special Meeting
21 Jun 2023 //
BUSINESSWIRE
Crescita Reports First Quarter 2023 Results
11 May 2023 //
BUSINESSWIRE
Crescita Reports Q4 and Fiscal 2022 Results
15 Mar 2023 //
BUSINESSWIRE
Crescita Reports Third Quarter 2022 Results
09 Nov 2022 //
BUSINESSWIRE
Crescita Reports Second Quarter 2022 Results
10 Aug 2022 //
BUSINESS WIRE
Crescita Announces Results of Annual General and Special Meeting of Shareholders
12 May 2022 //
BUSINESSWIRE
Crescita Reports First Quarter 2022 Results
11 May 2022 //
BUSINESSWIRE
Crescita to Present at Bloom Burton & Co. Healthcare Investor Conference
21 Apr 2022 //
BUSINESSWIRE
Crescita Reports Q4 and Fiscal 2021 Results
23 Mar 2022 //
BUSINESSWIRE
Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharma
13 Dec 2021 //
BUSINESSWIRE
Crescita Announces Canadian Distribution Agreement with Obagi Cosmeceuticals LLC
09 Sep 2021 //
BIOSPACE
Crescita Therapeutics and STADA Enter Exclusive Licensing Agreement for Pliaglis
18 Aug 2021 //
BUSINESSWIRE
Crescita Therapeutics Announces Agreement with Croma Pharma for Pliaglis®
28 Jun 2021 //
BUSINESSWIRE
Crescita Therapeutics Announces the Results of its Annual General a
12 May 2021 //
BUSINESSWIRE
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
25 Nov 2020 //
PRNEWSWIRE
Crescita Announces Licensing Agreement for Pliaglis® in China
05 Nov 2020 //
PRNEWSWIRE
Crescita to Receive One-time Cash Payment Following Amendment to Pliaglis®
28 Jul 2020 //
PRNEWSWIRE
Crescita to Receive One-time Cash Payment Following Amendment to Pliaglis®
28 Jul 2020 //
PRNEWSWIRE
Crescita Therapeutics Announces the Results of its Annual General Meeting
14 May 2020 //
PRNEWSWIRE
Crescita Therapeutics Announces Measures in Response to COVID-19 Virus
24 Mar 2020 //
PR NEWSWIRE
Crescita Announces +ve Topline Results from Two Pivotal Phase 3 Clinical Studies
11 Feb 2020 //
BUSINESSWIRE
Crescita Signs Exclusive Distribution Agreement with FILLMED
20 Jan 2020 //
PR NEWS WIRE
Crescita, TetraBio Collaborate to Enhance Delivery of Beta-Caryophyllene
04 Jan 2019 //
NASDAQ
Crescita Therapeutics™ Announces Acquisition of Alyria® Skincare Products
08 Aug 2017 //
PR NEWSWIRE
Crescita Therapeutics™ Announces the Appointment of a New President
12 Apr 2017 //
PR NEWSWIRE
Crescita Therapeutics™ Announces Approval of Pliaglis in Mexico
09 Sep 2016 //
PR NEWSWIRE
Crescita Therapeutics™ Inc. Announces Acquisition of INTEGA Skin Sciences
02 Sep 2016 //
PR NEWSWIRE
